This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
by Zacks Equity Research
Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.
CRMDPositive Net Change ARVNPositive Net Change IMCRNegative Net Change RXRXPositive Net Change
artificial-intelligence biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.
REGNPositive Net Change RAREPositive Net Change ARVNPositive Net Change IMCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bayer Beats on Q2 Earnings and Sales, Raises '25 Adjusted Sales View
by Zacks Equity Research
BAYRY beats on Q2 earnings and raises 2025 sales outlook (on a currency-adjusted basis) as pharma growth offsets currency and Xarelto headwinds.
REGNPositive Net Change JNJPositive Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Tidewater (TDW)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
TDWNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?
by Ekta Bagri
BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now.
BMYPositive Net Change PFEPositive Net Change BNTXNo Net Change
biotechnology biotechs earnings-report medical pharmaceuticals
Small-Caps Stay Higher, Other Indexes Dwindle
by Mark Vickery
President Trump mentioned adding new tariffs on semiconductor imports, which helped move markets aside from the Russell 2000 lower.
AMDNegative Net Change AMGNPositive Net Change SWKSPositive Net Change SMCINegative Net Change SNAPNegative Net Change
biotechnology earnings semiconductor social-media
ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised
by Zacks Equity Research
Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.
ZTSPositive Net Change CRMDPositive Net Change ARVNPositive Net Change IMCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
CPRX gears up to report Q2 results as Firdapse sales rise, Agamree grows, and Fycompa faces a post-patent dip.
CPRXPositive Net Change ACADNegative Net Change DNLIPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
by Ekta Bagri
EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook
by Zacks Equity Research
Krystal Biotech tops Q2 estimates with strong Vyjuvek sales, but shares fall 14% on weak Q3 revenue guidance.
BAYRYPositive Net Change CRMDPositive Net Change KRYSPositive Net Change IMCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.
PFEPositive Net Change EXASNegative Net Change AMRXPositive Net Change VTRSPositive Net Change
biotechnology medical pharmaceuticals
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.
ZTSPositive Net Change ACADNegative Net Change RXRXPositive Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, Ozempic and Rybelsus.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Central Garden (CENT)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CENTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
GILD Likely to Beat on Q2 Earnings: Buy, Sell or Hold the Stock?
by Zacks Equity Research
GILD eyes Q2 gains as demand for HIV drugs holds strong despite pricing pressures and cell therapy headwinds. We recommend investors to wait and watch for now.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
by Zacks Equity Research
Alnylam stock jumps 15% after a surprise Q2 profit, driven by soaring Amvuttra sales and raised 2025 revenue guidance.
REGNPositive Net Change ALNYNegative Net Change NVSPositive Net Change RHHBYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.
ZTSPositive Net Change EXASNegative Net Change BNTXNo Net Change
biotechnology biotechs earnings medical pharmaceuticals
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
by Zacks Equity Research
REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.
REGNPositive Net Change SNYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
After Golden Cross, Invesco (IVZ)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
IVZPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
by Ahan Chakraborty
BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.
BCRXNegative Net Change IONSPositive Net Change NTLANegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
by Zacks Equity Research
TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.
JNJPositive Net Change TEVANegative Net Change ABBVPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
by Zacks Equity Research
BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.
BMYPositive Net Change PFEPositive Net Change EXELPositive Net Change BNTXNo Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat
by Zacks Equity Research
BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical.
CRMDPositive Net Change BHCPositive Net Change ARVNPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy Medpace (MEDP) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
MEDPPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
New Strong Sell Stocks for July 31st
by Zacks Equity Research
CELZ, GRFS and WHR have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2025.
WHRPositive Net Change GRFSPositive Net Change CELZPositive Net Change
biotechnology